Saturday 17 October 2026
Export BCTX’s income statement to Excel — free account
BRIACELL THERAP
BCTX Healthcare Biotechnology
In the quarter to April 2026, EPS grew 94.0% and free cash flow was flat, each against the same quarter a year earlier.
3.42
0.35
−9.28%
Follow BCTX
BRIACELL THERAP (BCTX) P/E ratio
As of 16 October 2026, BRIACELL THERAP (BCTX) trades at a P/E ratio of 1.5×. Over the past ten years it has ranged from 0.0× (April 2026) to 55.7× (August 2017); the current reading is higher than 95% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 55.7×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| NXTC NextCure, Inc. compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| CRVO CervoMed Inc. compare | n/m |
| IRLA Quince Therapeutics, Inc. compare | n/m |
| BCTX BRIACELL THERAP | 1.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 3.1× |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)